Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities.

JHEP reports : innovation in hepatology·2021
Same author

A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.

Journal of hepatology·2020
Same author

Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.

Journal of hepatology·2020
Same author

New treatments/targets for primary biliary cholangitis.

JHEP reports : innovation in hepatology·2020
Same author

Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2019
Same author

Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival.

Gastroenterology·2018

Related Experiment Video

Updated: Jun 14, 2026

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

Primary biliary cirrhosis: a 2010 update.

Raoul Poupon1

  • 1UPMC Univ Paris 06, France; INSERM, UMR_S 938, Paris, France. raoul.poupon@sat.aphp.fr

Journal of Hepatology
|March 30, 2010
PubMed
Summary
This summary is machine-generated.

Primary biliary cirrhosis (PBC) is a rare autoimmune liver disease affecting middle-aged women. Ursodeoxycholic acid (UDCA) is the primary treatment, though some patients require further intervention.

Related Experiment Videos

Last Updated: Jun 14, 2026

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

Area of Science:

  • Hepatology
  • Immunology
  • Gastroenterology

Background:

  • Primary biliary cirrhosis (PBC) is a chronic, autoimmune liver disease targeting bile ducts.
  • It predominantly affects middle-aged women and can lead to cirrhosis and liver failure without treatment.
  • PBC is rare, with a prevalence under 1/2000, and arises from genetic and environmental factors.

Purpose of the Study:

  • To review current knowledge on the epidemiology of PBC.
  • To summarize the ethiopathogenesis and clinical manifestations of PBC.
  • To discuss the therapeutic strategies for managing PBC.

Main Methods:

  • Literature review of epidemiological data.
  • Analysis of studies on genetic and environmental risk factors.
  • Summary of clinical presentations and treatment outcomes.

Main Results:

  • PBC affects women predominantly and progresses over 10-20 years without treatment.
  • Genetic predisposition and environmental triggers are implicated in PBC development.
  • Ursodeoxycholic acid (UDCA) is effective for many, but 1/3 of patients show inadequate response.

Conclusions:

  • PBC requires comprehensive understanding of its multifaceted origins.
  • UDCA therapy offers a good prognosis for most, but alternative treatments are needed for non-responders.
  • Further research into novel therapies is crucial for patients with inadequate response to UDCA.